亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會(huì)員登錄|免費(fèi)注冊(cè)|忘記密碼|管理入口 返回主站||保存桌面|手機(jī)瀏覽|聯(lián)系方式|購(gòu)物車
企業(yè)會(huì)員第1年

隨州市紅旗化工有限公司  

醫(yī)藥原料醫(yī)藥中間體原料藥

搜索
新聞中心
  • 暫無(wú)新聞
產(chǎn)品分類
  • 暫無(wú)分類
聯(lián)系方式
  • 聯(lián)系人:閆先生
  • 電話:0722-3257386
  • 傳真:0722-3257381
  • QQ:1374834438
站內(nèi)搜索
 
榮譽(yù)資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無(wú)鏈接
首頁(yè) > 供應(yīng)產(chǎn)品 > 恩替卡韋 CAS:142217-69-4
恩替卡韋 CAS:142217-69-4
單價(jià) 面議對(duì)比
詢價(jià) 暫無(wú)
發(fā)貨 湖北隨州市付款后3天內(nèi)
型號(hào) 142217-69-4
過(guò)期 長(zhǎng)期有效
更新 2020-06-18 10:08
 
詳細(xì)信息
恩替卡韋
CAS:142217-69-4
英文名: Entecavir
別名:2-Amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one
產(chǎn)品名稱: 恩替卡韋; 9-(4-羥基-3-羥甲基-2-亞甲基環(huán)戊-1-基)鳥(niǎo)嘌呤
分子式:C12H15N5O3
分子量:277.28
含量:99%
標(biāo)準(zhǔn):usp
性狀:白色粉末
用途:最新抗乙肝病毒的一線藥物
包裝:根據(jù)客戶要求
©2025 隨州市紅旗化工有限公司 版權(quán)所有   技術(shù)支持:化工網(wǎng)   訪問(wèn)量:31230  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |